CONCLUSION: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas.PMID:35405680 | DOI:10.1159/000524500 (Source: Oncology)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου